title: [Efficacy of erlotinib after gefitinib administration in patients with non-small cell lung cancer].
abstract: We retrospectively evaluated the survival benefit of dispensing erlotinib after gefitinib administration in patients with nonsmall cell lung cancer. Ninety patients treated with erlotinib in our hospital were divided into two groups: G+ group patients who were treated with erlotinib with prior gefitinib administration, and G- group patients who were treated with erlotinib without prior gefitinib administration. Median survival time (MST) in all 90 patients was 275 days. MST of 22 patients in the G+ group was shorter than that of 68 patients in G- group, but this difference was not statistically significant (283 days vs 177 days, p=0. 329). MST in 19 patients of the G+group who were administered erlotinib for over 1 month was shorter than that of 49G-group patients who were administered erlotinib over 1 month. However, this difference was also not statistically significant(395 days vs 238 days, p=0. 575). Univariate analysis demonstrated that EGFR mutation unknown, time to progression (TTP) with gefitinib longer than 1 year, gefitnib administration longer than 1 year, and responder to gefitinib, suggest a better prognosis. Mutivariate analysis revealed that only TTP with gefitinib longer than 1 year was an independent prognostic factor for patients in the G+ group.
authors.affiliation: Dept. of Respiratory Medicine, Juntendo University, Faculty of Medicine.
authors.forename: Akiko
authors.initials: A
authors.lastname: Murakami
authors.forename: Rina
authors.initials: R
authors.lastname: Ohashi
authors.forename: Kunihiko
authors.initials: K
authors.lastname: Minakata
authors.forename: Ryo
authors.initials: R
authors.lastname: Koyama
authors.forename: Keiko
authors.initials: K
authors.lastname: Muraki
authors.forename: Takehito
authors.initials: T
authors.lastname: Shukuya
authors.forename: Yukiko
authors.initials: Y
authors.lastname: Namba
authors.forename: Ryo
authors.initials: R
authors.lastname: Ko
authors.forename: Shigehiro
authors.initials: S
authors.lastname: Yagishita
authors.forename: Yoko
authors.initials: Y
authors.lastname: Katsura
authors.forename: Fumiyuki
authors.initials: F
authors.lastname: Takahashi
authors.forename: Shoko
authors.initials: S
authors.lastname: Sakuraba
authors.forename: Kazuhisa
authors.initials: K
authors.lastname: Takahashi
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000175:diagnosis / Q000188:drug therapy*; D000069347:Erlotinib Hydrochloride; D005260:Female; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011799:Quinazolines / Q000008:administration & dosage; D012189:Retrospective Studies
chemical_list: D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; D000077156:Gefitinib